Archives in cancer research最新文献

{"title":"Innovative method for early detection of skin cancer based on frequency analysis","authors":"Shabnam Kia, S. Setayeshi, M. Pouladian, H. Ardehali","doi":"10.21767/2254-6081-C2-009","DOIUrl":"https://doi.org/10.21767/2254-6081-C2-009","url":null,"abstract":"Background: Membranoproliferative glomerulonephritis (MPGN) is a type of glomerulonephritis caused by deposits in the kidney glomerular mesangium and basement membrane thickening, activating complement and damaging the glomeruli. (MPGN) classified to 3 types according to location of deposits, and based on etiology categorized to secondary and idiopathic. Objective: The aim of the study is to find the outcome of treatment (remission, partial remission, relapse and progress to end stage renal disease) of idiopathic membranoproliferative glomerulonephritis, among adult Sudanese patients presenting to Omdurman Military Hospital, Renal Unit. Materials & Methods: A retrospective study of patients with idiopathic MPGN followed up at the clinic. 45 patients with no identifiable cause of MPGN were included. Idiopathic (MPGN) patients who have high renal profile or nephrotic range treated by three doses of methylprednisolone 0.5 g intravenous in three consecutive days and of corticosteroid tabs (0.5_1mg/kg/day), slowly withdrawn according to the patient response indicated by spot urine test . Results: Out of 45 patients, the following treatment outcomes were observed, (remission, partial remission, relapsed, and progressed to (ESRD) ), ( 44% , 16% , 18% , 22% ) respectively . Conclusions: In comparison to the similar studies, the remission rate is comparable, but the renal survival rate is different.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68127603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Tumor Response and Change in EQ5D-3L Quality of Life among Cancer Patients","authors":"Stephen Joseph Garcia, C. V. Uy, C. Ngelangel, Francisco delos Reyes","doi":"10.21767/2254-6081.1000142","DOIUrl":"https://doi.org/10.21767/2254-6081.1000142","url":null,"abstract":"Introduction: The primary aim in cancer treatment is to provide excellent tumor response while maintaining the most acceptable quality of life. The relationship of QoL to tumor response has not yet been well discussed. This study determines the association between the change in the QoL from baseline to one year follow-up and tumor response among patients enrolled in the ASEAN Cost in Oncology (ACTION) study. \u0000Methods: Pooled data from the ACTION study was reviewed. Associations between demographics, cancer type, and tumor response were analyzed. \u0000Results: Of the qualified profiles (412/ 742), breast cancer (42.2%), colorectal (21.8%), and head neck (10%) are still most common. Of these cases, 126 (30.6%) were metastatic on presentation. Demographic data showed female sex having better tumor response. More importantly, tumor response was significantly associated with improvement in QoL: complete or partial response was associated with improvement in QoL (p=.000) while progressive disease related to worse situations. The general pattern seen above was reflected in female breast cancer cases, colon and rectal cancer, and other malignant neoplasms. \u0000Conclusion: Improvement in QoL was significantly associated with better tumor response. This trend was similar for breast cancer, colorectal cancer and other malignancies. The use of universal measures of health like the EQ5D-3L may be used to quantify improvements in QoL with several limitations: 1) Cultural differences should be established and 2) Limitations in quantifying precise changes in QoL. The utilization of more culturally adept QoL measures may address this problem. Similarly, the use of secondary data may limit the results in this study. Prospective studies specifically addressing the objectives may improve results.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"5 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.1000142","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44261915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical immunogenic chemotherapy in refractory sarcoma","authors":"Pedro Alej, ro Lucero Diaz","doi":"10.21767/2254-6081-c1-006","DOIUrl":"https://doi.org/10.21767/2254-6081-c1-006","url":null,"abstract":"","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"62 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82216527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biochemical Meaning of Defective Immune:Surveillance in Cancer Patients","authors":"Tsuneo Kobayashi","doi":"10.21767/2254-6081.100174","DOIUrl":"https://doi.org/10.21767/2254-6081.100174","url":null,"abstract":"Background: For a long time, phenomenon of defective immune-surveillance in cancer patients from pathological standpoint was not elucidated. I have reported 1985 that lowering seral cyclic AMP is biochemical reason of defective immunesurveillance from adoptive lymphocyte immunotherapy experiment among cancer patients. Recently, Honjo Tasku et al., reported why T cell don’t attack cancer cells by the covering of PD-L1 on its receptor of PD-1. This is also one of defective immune-surveillance from cellular side. I have recently surveyed the correlation between seral cyclic AMP concentration and immune activity in cancer patients. I have confirmed the biochemical reason of lowering cyclic AMP leads to seral defective immune-surveillance in cancer patient’s serum. Methods: I have surveyed seral cyclic AMP concentration and T cell number and NK cell among 40 cancer patients and preclinical cancer patients. Results: The averaged seral cyclic AMP has a positive tendency between lower immune activity and lower cyclic AMP in the serum when cancer is developing beforehand. Conclusion: As cyclic AMP is elevated after fasting therapy, adoptive lymphocyte immunotherapy become useful as immuno-potentiation even if in advanced cancer patients.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100174","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy for Large Single Brain Metastasis of Non-Small Cell Lung Cancer: A Case Report","authors":"Choi Jh","doi":"10.21767/2254-6081.100182","DOIUrl":"https://doi.org/10.21767/2254-6081.100182","url":null,"abstract":"Background: Lung cancer is the most common primary site of brain metastases. Patients with a single brain metastasis from non-small cell lung cancer (NSCLC) have the potential for long term survival. Case report: A 39-year-old man presented stage IIIB (cT2N3M0) NSCLC. He underwent concurrent chemoradiotherapy. Follow-up chest CT and PET-CT showed complete tumor remission. The patient had headache and visual symptom 18 months after completion of treatment. The brain MRI showed metastatic brain mass. The size of single mass was 6.6 cm. He refused surgical procedure for brain lesion. He received radiation therapy. Total dose to PTV was 30 Gy in 5 fractions. The radiation therapy was well tolerated. Partial response of brain lesion was achieved and remained stable for 10 months until bone metastasis was found. Conclusions: Fractionated stereotactic radiotherapy (FSRT) in the current study could achieve good local tumor control and prevent neurological symptoms from worsening.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100182","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Competitive Treatment in Diffuse LargeB-cell lymphoma (DLBCL) and theFuture SOC for the First Line Therapy","authors":"T. Allen, G. Razavi, Nepton Sheik Khoni, N. Basha","doi":"10.21767/2254-6081.100171","DOIUrl":"https://doi.org/10.21767/2254-6081.100171","url":null,"abstract":"Diffuse large B-cell lymphoma (DLBCL) in the most common type of non-Hodgkin’s lymphoma (NHL) in developed world, so far and approximately 60,000 new non-Hodgkin lymphoma (NHL) cases and 20,000 deaths have been estimated in the United States for 2010. In spite of novel therapeutic options have been suggested and successfully tried in patients with lymphoproliferative disorders, the standard first- line treatment for DLBCL has remained the same combination of chemotherapy and CD20 (activated-glycosylated phosphoprotein) targeting monoclonal antibody rituximab (R) with 30% to 40% chance of relapse after first line R-CHOP treatment. Several clinical trials have been designed to evaluate safety, efficacy and superior clinical benefit by adding novel agents, intensifying cycles of treatment or substituting rituximab with new CD20 targeting immunotherapies. Intensification of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) chemotherapy from 3- week interval cycles to 2- week interval cycles has already shown clinical benefit in a German trial but failed to show improved overall and disease free (DFS1) survival in both elderly (60 to 80 years) and young patients in randomized phase 3 clinical trials. Namely, in a phase 2 randomized clinical trials (PYRAMID) as a first line treatment for non- Germinal Center Cell (GCB) subtype of DLBCL the results were in favor of R-CHOP and adding bortezomib was not found to improve DFS and OS significantly. Immunomodulatory agent lenalidomide is another attractive therapeutic option for non-GCB subtype of DLBCL. Statistically significant difference between non-GCB and GCB controls treated with standard R-CHOP alone in terms of progression-free survival (28% vs. 64%; P = 0.00029) and overall survival (46% vs. 74%; P = 0.000036) was reported while non-GCB and GCB treated with R-CHOP plus lenalidomide had similar rates of progression (60% vs. 59%; P = 0.83) and overall survival at 2 years (83% vs. 75%; P = 0.61). Despite these promising clinical results, further clinical studies, especially phase 3 randomized clinical trials are required to confirm the alternate competitive treatment for DLBCL patients.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100171","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gynaecological Lymphomas: Case Reports and Literature Review of Primary Extranodal Female Genital Tract and Breast Non-Hodgkin Lymphomas","authors":"Seidler Sj, Lovey Py, Busuioc Ci, H. De","doi":"10.21767/2254-6081.100186","DOIUrl":"https://doi.org/10.21767/2254-6081.100186","url":null,"abstract":"Primary extra nodal gynaecological lymphomas are rare, but their diagnosis is crucial since their treatment differs from the treatment of primary gynaecological malignancies. Throughout presentation of three case reports and a literature review, clinical, radiologic, pathologic and therapeutic aspects of primary extra nodal gynaecological lymphomas will be discussed. The first case is about a 50-yearsold woman diagnosed with a cervical DLBCL successfully treated with R-CHOP chemotherapy. The second case concerns 30-years-old, 3G 0P, woman diagnosed with endometrial lymphoma after a third spontaneous miscarriage. The third is an 80-years-old woman diagnosed with right breast cancer and simultaneous left MALT lymphoma. Large homogenous masses and unusual presentation mode, especially among young patients, should raise the attention towards lymphoma. Biopsy is the key examination for the diagnosis of lymphoma. Once primary extranodal gynaecological location is confirmed, treatment essentially consists of chemotherapy, with or without radiotherapy, and thus widely differs from the treatment of primary gynaecological tumors.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100186","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68126642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Telomerase biology affects cancer biology, chemotherapy and aging","authors":"J. S. Sonneborn","doi":"10.21767/2254-6081-C4-013","DOIUrl":"https://doi.org/10.21767/2254-6081-C4-013","url":null,"abstract":"","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"06 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68130882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of the Response to Chemotherapy in the Treatment of Hodgkin's Disease at the Mother and Child Center of the Chantal Biya's Foundation in Yaounde, Cameroon.","authors":"Pondy Angele Hermine, Djomgoue Molom Rodrigue, Ngo Nonga Bernadette, Koki Ndombo Paul","doi":"10.21767/2254-6081.100168","DOIUrl":"https://doi.org/10.21767/2254-6081.100168","url":null,"abstract":"Background: Hodgkin’s disease (HD) is a malignant disorder of the lymphatic tissue which mainly affects the lymph nodes and is characterized by a particular cell called Reed Sternberg cell. It represents 5% to 10% of malignancies in children with two peaks one around 6 years and the other around 14 years. Objective: The aim of the study was to evaluate the response of HD to a chemotherapy regimen without radiotherapy. Methods: We conducted a prospective study from 2007 to 2016. Were included, all records of patients admitted for Hodgkin's disease and having a histological evidence of HD. Children were treated with the protocol COPP/ABV at the Mother and Child Center of the Chantal Biya’s Foundation in Yaounde using only chemotherapy. Results: During that period, we collected 26 cases of HD. Which represented 1.96% of all cancers in children. The mean age at diagnosis was 11.6 years (7-16 years). The most represented age group was that of 10 to 14 with 57.7% of the cases. The sex ratio was 1.88. Forty-two per cent of patients had consulted more than 12 months after the beginning of symptoms. The circumstances of discovery were dominated by the appearance of peripheral adenopathies, particularly cervical (76.9%). Signs of clinical evolution were found at diagnosis in 61.5% of patients. The scleronodular, mixed cellular and the lymphocyte-rich forms were found in the following respective proportions: 38.4%, 34.6% and 27% and 82.60% of our patients were classified as unfavourable prognosis at the time of diagnosis. Overall survival at 5 years was estimated to be 82%. Conclusion: Hodgkin’s disease is a chemo sensitive and radiosensitive disease, for which most international protocols combine the two modalities of treatment. This study has demonstrated the feasibility of this modified treatment in our context where radiotherapy is unavailable.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.21767/2254-6081.100168","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68124205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Rare Case of SubmandibularGland Metastasis as the First Sign ofAdenocarcinoma of the Lung","authors":"A. Jihan, Moukasse Yasmina, Sfaoua Hasnae, A. Asma, Lahlali Fatima Zahra, E. Sanae, K. Tayeb, Elkacemi Hanan, B. Noureddine","doi":"10.21767/2254-6081.100175","DOIUrl":"https://doi.org/10.21767/2254-6081.100175","url":null,"abstract":"The current study document is an unusual case of submandibular metastasis as the first sign of adenocarcinoma of the lung. We report a 57-year-old male chronic smoker presented with a tumefaction in the submandibular gland. The patient had a complete excision. At the histological examination, the diagnosis of an undifferentiated carcinoma of the submandibular gland was retained. A systemic work-up was performed, which unexpectedly detected a tumor in the right lung and was confirmed by histopathological examination. Despite their rarity, submandibular lesions should be considered as possible manifestations of underlying malignancies.","PeriodicalId":91204,"journal":{"name":"Archives in cancer research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68125355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}